About Us

Theranovir team brings expertises in drug development with scientific, clinical, financial and industry background.

Operational Team

Zakia BELAID-SANDAL (PhD)

HEC-Challenge+

Chief Executive Officer, Founder

17 years of experience in leading and participating in oncology programs in France and abroad

4 co-invented patents

Alexandre FONTAYNE (PhD)

Chief CMC Officer

Former President of Biothelis, SAS. President and expert of B4S consulting; Involved in ublituximab, roledumab and murlentamab development

Adyl CHAHET

Chief Financial Officer

President of Financyal, outsourced CFO, helps companies optimize financial strategy, performance, and growth. Ex-Deloitte M&A and Bpifrance private equity, expert in financial analysis, valuation, and deal structuring. Holds a Master’s in Financial Engineering (Paris 1 Panthéon-Sorbonne) and studied banking & finance in Switzerland.

Bords of directors

Zakia BELAID-SANDAL (PhD)

HEC-Challenge+

Chief Executive Officer, Founder, Board Member

17 years of experience in leading and participating in oncology programs in France and abroad 4 co-invented patents

Alexander EGGERMONT (MD, PhD)

Non executive director , Board Member

KOL for immuno-onco therapies, experience in leading European cancer institutions.

Gilles COTTIER (PhD)

Non executive director , Board Member

Former CEO of Actylis; Former Executive VP Sigma-Aldrich; Broad industry domain expertise; Serves as an advisor to multiple companies

Medical and Scientific Advisory Board

Zakia BELAID-SANDAL (Phd)
HEC-Challenge+

17 years of experience in leading and participating in oncology programs in France and abroad 4 co-invented patents

Giorgio Massimini (PhD, MD)

Former VP Early Clinical Oncology at MerckGroup; over 40 years of experience in pharma. Previous clinical responsible for the development of Aromasin;Sutent,Tepmekoet others oncology drugs consultant for biotech companies